<DOC>
	<DOCNO>NCT02570893</DOCNO>
	<brief_summary>This multicenter , randomize , open-label , phase III trail compare adjuvant chemoradiotherapy ( Paclitaxel carboplatin ) adjuvant radiotherapy patient undergoing radical esophagectomy pathologic lymph node positive esophageal squamous cell carcinoma .</brief_summary>
	<brief_title>A Phase III Trail Adjuvant Chemoradiotherapy Versus Adjuvant Radiotherapy Esophageal Squamous Cell Carcinoma</brief_title>
	<detailed_description>Patient Population : Age : 18-70y ; Thoracic esophageal squamous cell cancer undergo radical esophagectomy ; Clinical stage T1-4 , N1-3 , M0 ; Eastern Cooperative Oncology Group ( ECOG ) score : 0-1 ; The patient randomize 2 arm . Arm A : Adjuvant radiotherapy ( 50.4gray/28fraction ) follow chemotherapy ( Paclitaxel carboplatin ) 4 cycle . Arm B : Adjuvant radiotherapy ( 50.4gray/28fraction )</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>1 . Histologically document squamous cell carcinoma thoracic esophagus ; undergoing radical esophagectomy ; pathological stage T ( primary tumor ) 14 N ( regional lymph node ) 13 M ( distant metastasis ) 0 ( ESOPHAGUS , Union International Cancer Control ( UICC ) 2010 ) ; 2 . Untreated ( e.g . radiotherapy , chemotherapy , target therapy immunotherapy ) ; 3 . The expectation life 6 month ; 4 . Age : 18~70 year old ; 5 . Normal hemodynamic index recruitment ( include white blood cell count &gt; 4.0×109/L , neutrophil count &gt; 1.5×109/L , platelet count &gt; 100×109/L , hemoglobin≥90g/l , normal liver/kidney function ) ; 6 . ECOG ( Eastern Cooperative Oncology Group ) : 01 ; 7 . Able understand study sign informed consent . 1 . Have treat chemotherapy , radiotherapy anti tumor treatment except surgery ; 2 . Known suspected allergy paclitaxel carboplatin ; 3 . Female pregnancy lactating ; 4 . With significant psychological , family , social factor may affect ability understand sign inform consent ; 5 . Patients peripheral neuropathy ( CTC grade≥2 ) ; 6 . With malignant tumor recruitment . 7 . The researcher consider patient appropriate enroll study ; 8 . The patient ca n't tolerant postoperative adjuvant radiotherapy chemotherapy serious heart/lung/liver/kidney function , haematopoietic system disease , immune system diseases , nervous system disease , cachexia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Esophageal cancer ; adjuvant therapy ; chemotherapy ; radiotherapy</keyword>
</DOC>